報價延遲最少15分鐘:2025/06/01 13:09 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.42 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.24/-5.28
|
|
企業價值
94.88M
|
| 資產負債 |
|
每股賬面淨值
10.39
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/01 13:09 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity. |